Effective treatments and vaccines are lacking for parainfluenza virus 3 (PIV3). Here the authors isolate human monoclonal antibodies (mAb) targeting the hemagglutinin-neuraminidase protein of PIV3 and, using cryo-EM, describe the epitope of a cross-neutralizing and protective mAb.
- Rose J. Miller
- Ian A. Durie
- Jarrod J. Mousa
